These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 19252821)
1. Correlation of alternative splicing of the D2 dopamine receptor mRNA and estrogen receptor mRNA in the prolactinomas and gonadotrope tumors. Wu ZB; Li CZ; Zong XY; Su ZP; Zeng YJ; Zhang YZ J Neurooncol; 2009 Aug; 94(1):135-9. PubMed ID: 19252821 [TBL] [Abstract][Full Text] [Related]
2. Selective expression of estrogen receptor alpha and beta isoforms in human pituitary tumors. Shupnik MA; Pitt LK; Soh AY; Anderson A; Lopes MB; Laws ER J Clin Endocrinol Metab; 1998 Nov; 83(11):3965-72. PubMed ID: 9814476 [TBL] [Abstract][Full Text] [Related]
3. Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. Wu ZB; Zheng WM; Su ZP; Chen Y; Wu JS; Wang CD; Lin C; Zeng YJ; Zhuge QC J Neurooncol; 2010 Aug; 99(1):25-32. PubMed ID: 20063113 [TBL] [Abstract][Full Text] [Related]
4. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Caccavelli L; Feron F; Morange I; Rouer E; Benarous R; Dewailly D; Jaquet P; Kordon C; Enjalbert A Neuroendocrinology; 1994 Sep; 60(3):314-22. PubMed ID: 7969790 [TBL] [Abstract][Full Text] [Related]
5. Differential expression of estrogen receptor-beta (ER beta) in human pituitary tumors: functional interactions with ER alpha and a tumor-specific splice variant. Chaidarun SS; Swearingen B; Alexander JM J Clin Endocrinol Metab; 1998 Sep; 83(9):3308-15. PubMed ID: 9745446 [TBL] [Abstract][Full Text] [Related]
6. Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland. Oomizu S; Boyadjieva N; Sarkar DK Alcohol Clin Exp Res; 2003 Jun; 27(6):975-80. PubMed ID: 12824819 [TBL] [Abstract][Full Text] [Related]
7. Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas. Su Z; Wang C; Wu J; Jiang X; Chen Y; Chen Y; Zheng W; Zhuge Q; Wu Z; Zeng Y Neurol Sci; 2012 Apr; 33(2):275-9. PubMed ID: 21748460 [TBL] [Abstract][Full Text] [Related]
8. Each individual isoform of the dopamine D2 receptor protects from lactotroph hyperplasia. Radl D; De Mei C; Chen E; Lee H; Borrelli E Mol Endocrinol; 2013 Jun; 27(6):953-65. PubMed ID: 23608643 [TBL] [Abstract][Full Text] [Related]
10. Either isoform of the dopamine D2 receptor can mediate dopaminergic repression of the rat prolactin promoter. McChesney R; Sealfon SC; Tsutsumi M; Dong KW; Roberts JL; Bancroft C Mol Cell Endocrinol; 1991 Aug; 79(1-3):R1-7. PubMed ID: 1834494 [TBL] [Abstract][Full Text] [Related]
11. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas. Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401 [TBL] [Abstract][Full Text] [Related]
12. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes. Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350 [TBL] [Abstract][Full Text] [Related]